FIGURE 3 from Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations

Kana Ohashi,Makiko Yamashita,Hiromi Sakamoto,Atsuhiko Kato,Yukihiro Mizoguchi,Yae Kanai,Yukiko Sonobe,Noriaki Sawada,Tomoyoshi Soga,Shigehisa Kitano,Keisuke Tsukada,Kazuki Yasuda,Mina Takahashi,Osamu Natori,Yoko Kayukawa,Risa Mitsumori,Yukari Nishito,Yukihiro Yoshida,Akiyoshi Hirayama,Yasuhito Arai,Nami Yabuki,Shumpei Niida,Hiroyuki Tsunoda,Kosuke Arai,Toru Maruyama,Etsuko Fujii,Hideaki Mizuno,Shun-Ichi Watanabe,Noriko Motoi,Kazunori Aoki,Hironori Fukuda,Yuki Nagata,Teruhiko Yoshida,Tatsuhiro Shibata,Kouichi Ozaki,Atsushi Ochiai,Nobuyoshi Hiraoka,Takio Kitazawa ,Etsuko Hashimoto ,Mikio Shimada ,T Nishizawa

doi:10.1158/2767-9764.23509033

Abstract

Patient outcomes in immune subtypes. A and B, Kaplan–Meier EFS curves for subtypes of LUAD (A) and LUSQ (B). P values were calculated by multivariate Cox regression. C and D, Relationships of cell density (left) with �45 (right) for each immune cell type infiltrated in tumors to patient prognosis in LUAD (C) and LUSQ (D). Z-scores from Cox proportional hazards analysis are plotted; in the plots, red dots indicate P ≤ 0.05. E and F, Differences in histopathologic findings for immune subtypes of LUAD (E) and LUS (F). The P values determined using Fisher exact test w are plotted; in the plots, red circles indicate P ≤ 0.05 and filled red circles indicate Holm-adjusted P ≤ 0.2. G and H, Frequencies of each classification in immune subtypes in LUAD (G) and LUSQ (H). Numbers of patients are indicated in the bar segments.

Full Text